12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Halaven eribulin mesylate regulatory update

The German Institute for Quality and Efficiency in Health Care (IQWiG) said breast cancer drug Halaven eribulin mesylate from Eisai provides "no additional benefit" over chemotherapy. IQWiG's report compared Halaven to monotherapy consisting of capecitabine, 5-fluorouracil, or vinorelbine, as well as anthracycline or taxane-containing therapy for those patients for whom it is still an option....

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >